APA (7th ed.) Citation

Subbiah, V., Bashir, B., El-Khoueiry, A., Punekar, S., Khawaja, M., Gutierrez, M., . . . Yap, T. (2025). 998TiP GUARDIAN-101: A first in human, tumor agnostic phase I study evaluating safety and preliminary antitumor activity of CLSP-1025, a first in class, HLA-directed T cell engager (TCE) for advanced solid tumors harboring the p53 R175H mutation. Annals of Oncology, 36, S652. https://doi.org/10.1016/j.annonc.2025.08.1567

Chicago Style (17th ed.) Citation

Subbiah, V., et al. "998TiP GUARDIAN-101: A First in Human, Tumor Agnostic Phase I Study Evaluating Safety and Preliminary Antitumor Activity of CLSP-1025, a First in Class, HLA-directed T Cell Engager (TCE) for Advanced Solid Tumors Harboring the P53 R175H Mutation." Annals of Oncology 36 (2025): S652. https://doi.org/10.1016/j.annonc.2025.08.1567.

MLA (9th ed.) Citation

Subbiah, V., et al. "998TiP GUARDIAN-101: A First in Human, Tumor Agnostic Phase I Study Evaluating Safety and Preliminary Antitumor Activity of CLSP-1025, a First in Class, HLA-directed T Cell Engager (TCE) for Advanced Solid Tumors Harboring the P53 R175H Mutation." Annals of Oncology, vol. 36, 2025, p. S652, https://doi.org/10.1016/j.annonc.2025.08.1567.